Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Preleukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Neoplasms by Histologic Type 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphoma 2Lymphatic Diseases 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphoid 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Leukemia 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Bone Marrow Diseases 2Venentoclax 1Primary Myelofibrosis 1Older Patients 1Non-Malignant Neoplasm 1Myeloproliferative Disorders 1Leukemia, Prolymphocytic 1Leukemia, Myelomonocytic, Chronic 1

Interventions

venetoclax 1fludarabine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Venentoclax × fludarabine × Other neoplasm × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡